Semaglutide (Rybelsus®) accepted for restricted use within NHS Scotland

Oral semaglutide is approved for treatment of adults with insufficiently controlled type 2 diabetes in addition to other oral anti-diabetic medicines, or as an add-on to basal insulin, as an alternative glucagon-like peptide-1 receptor agonist option.

SPS commentary:

The Scottish Medicines Consortium (SMC) has previously approved semaglutide subcutaneous injection (Ozempic) for restricted use. The SMC state prescribers should note that the effect of switching between oral and subcutaneous semaglutide cannot easily be predicted because of high pharmacokinetic variability of oral semaglutide; and clinical effectiveness should be considered when making switching decisions between formulations.


Scottish Medicines Consortium